NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Lowered by Wall Street Zen

Posted by on Aug 17th, 2026

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities research analysts also recently commented on NRXP. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 10th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Finally, BTIG Research lowered their target price on NRx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Check Out Our Latest Research Report on NRx Pharmaceuticals

NRx Pharmaceuticals Stock Performance

NRXP stock opened at $3.27 on Friday. NRx Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $5.05. The business’s 50 day moving average is $3.80 and its 200-day moving average is $2.96. The firm has a market cap of $118.47 million, a P/E ratio of -5.95 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million. Sell-side analysts forecast that NRx Pharmaceuticals will post -0.3 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors have recently modified their holdings of NRXP. Geode Capital Management LLC boosted its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Vanguard Group Inc. grew its stake in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Two Sigma Investments LP lifted its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $107,000. Finally, Bleakley Financial Group LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter valued at about $318,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

Read More

Analyst Recommendations for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.